Wednesday, July 8, 2026

Patent intelligence · US

US 10532032

Rolled collagen carrier

granted A61KA61K31/407A61K31/435A61K31/55
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 14
Applicant portfolio 1,436
Patent details — US 10532032
Jurisdiction
US
Status
granted
Grant date
Jan 14, 2020
Expiration
Jan 9, 2040
Applicant
TAKEDA AS
Claims
14
CPC classes
A61K, A61K31/407, A61K31/435, A61K31/55
View on Google Patents ↗

Quick answer

US 10532032 (Rolled collagen carrier) is held by TAKEDA AS. Status: granted. Granted Jan 14, 2020. Expires Jan 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
TAKEDA AS
Grant date
Expiration
Claims
14
CPC classes
A61K, A61K31/407, A61K31/435, A61K31/55, A61K38/363, A61K38/4833

More from TAKEDA AS

Related pharmaceutical patents in our USPTO index.

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Expires Sep 25, 2045

    granted
  2. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  3. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  5. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Expires Sep 4, 2045

    granted
  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted
  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 10532032?

US 10532032 (Rolled collagen carrier) is held by TAKEDA AS. Status: granted. Granted Jan 14, 2020. Expires Jan 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10532032?

TAKEDA AS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.

When does US 10532032 expire?

Our index shows an expiration date of Jan 9, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.